Intuitive Q3 2026 Earnings: Procedure Growth and System Demand Remain Strong, but Pricing Actions Reset Revenue-Per-Procedure Outlook

Intuitive Surgical reported Q3 2026 revenue of $3.05B, up 22% year over year, while non-GAAP diluted EPS increased 25% to $3.00. GAAP diluted EPS fell to $1.49 from $1.95 a year earlier, primarily because Intuitive recorded a $450M pre-tax charge related to a proposed antitrust litigation settlement.

The quarter showed continued broad-based adoption across da Vinci and Ion, with procedure volume rising 15% and da Vinci system placements rising 28%. The larger investment issue has shifted toward Intuitive’s decision to lower instrument costs in selected benign procedures and China, a strategy intended to widen adoption but expected to reduce da Vinci instruments-and-accessories revenue per procedure by 3% to 5% once fully implemented.

As Reported on the Call

The Bigger Story

Intuitive’s operating momentum remained intact in Q3. Procedures grew at a mid-teens rate, revenue grew faster than procedures, and the company expanded its installed base through stronger placements of da Vinci 5, SP, XiR, and Ion systems.

However, management is deliberately accepting lower instruments-and-accessories revenue per procedure in certain settings to reduce the economic barrier to robotic surgery. The strategy targets high-volume benign procedures, including cholecystectomy and inguinal hernia repair, as well as the China market, where policy-driven pricing changes begin in November.

That makes the key debate less about whether Intuitive can sustain demand for its systems and more about whether lower procedure costs produce enough incremental utilization, system demand, and market expansion to offset the pressure on revenue per procedure. Management expects the combined pricing initiatives to reduce da Vinci instruments-and-accessories revenue per procedure by approximately 3% to 5% on a mix-constant basis once fully implemented.

Revenue and Operating Performance

Revenue increased 22% to $3.05B, ahead of the company’s 15% combined procedure growth rate. Management attributed the difference primarily to higher system placements, growth in operating lease revenue, a larger installed base, and a richer mix of newer platforms.

Instruments and accessories revenue increased 18% to $1.80B. The gain was supported by approximately 14% da Vinci procedure growth and 31% Ion procedure growth. Da Vinci instruments-and-accessories revenue per procedure was approximately $1,860, compared with $1,800 a year earlier. Management said the increase reflected greater use of SP procedures and da Vinci 5-specific instruments, partly offset by procedure mix.

Systems revenue rose 30% to $769M as da Vinci placements increased to 546 systems from 427 a year earlier. The company placed 315 da Vinci 5 systems, compared with 240 in Q3 2025. It also placed 65 XiR systems, 42 SP systems, 37 X systems, and 87 Xi systems.

The placement mix illustrates Intuitive’s effort to cover a broader range of hospital and outpatient customer needs. Da Vinci 5 remained the largest contributor to system placements, while XiR is becoming more important for customers prioritizing a lower-cost platform, particularly in ambulatory surgery centers and international markets.

Operating lease arrangements remained a meaningful contributor to placements. Intuitive placed 291 da Vinci systems under operating leases, including 160 under usage-based operating leases, compared with 231 operating lease placements and 115 usage-based placements a year earlier. Lease growth supports systems revenue in the period but also builds a recurring revenue base over time.

Services revenue increased 22% to $482M, reflecting the larger installed base and a higher mix of da Vinci 5 systems. The da Vinci installed base reached 12,094 systems, up 12% from a year earlier, while the Ion installed base reached 1,152 systems, up 21%.

International markets were a notable contributor. Da Vinci procedure growth outside the U.S. was 20%, compared with 10% in the U.S. Europe, Asia, and Rest of World all posted roughly 20% growth or better. Intuitive also placed 211 da Vinci systems outside the U.S., up 29% year over year, including 115 systems in Europe.

Profitability and Margins

The headline GAAP earnings decline was driven primarily by litigation rather than deterioration in the underlying business. GAAP operating income fell to $593M from $760M, while GAAP net income attributable to Intuitive fell to $523M from $704M.

The company recorded a $450M pre-tax charge in selling, general, and administrative expense tied to a proposed settlement of antitrust class action litigation involving third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. The settlement remains subject to preliminary and final court approval. The charge reduced GAAP diluted EPS by approximately $0.99, net of tax, according to the company.

Excluding litigation and other non-GAAP adjustments, operating performance was substantially stronger. Non-GAAP operating income increased 30% to $1.27B, and non-GAAP operating margin was 42% of revenue. Management said the margin would have been 41% excluding a $28M pre-tax benefit from refunds of tariffs paid in earlier periods.

Non-GAAP gross margin expanded to 69.9% from 68.0%. Excluding the tariff-refund benefit, management said non-GAAP gross margin would have been 68.9%, still 90 basis points above the prior-year quarter. Product cost reductions and fixed-cost leverage were the primary underlying drivers.

Operating expenses rose faster than revenue on a non-GAAP basis, increasing 18% year over year. Management cited higher variable compensation, headcount, and prototype spending as development programs advanced. Research and development spending continued to grow faster than SG&A, reflecting investment in platform development, digital capabilities, artificial intelligence, and new procedure opportunities.

Investors should also note that non-GAAP earnings exclude share-based compensation, which was $216M in Q3 and remains a significant recurring expense.

Demand, Customers and Pricing

Demand appeared broad-based across Intuitive’s portfolio. Total da Vinci and Ion procedures increased 15%, and average system utilization rose 2%, according to management. Nearly 7,000 customers in more than 70 countries performed da Vinci procedures during the quarter.

U.S. da Vinci procedure growth of 10% was steady on a two-year basis but represented a slower reported growth rate than recent periods, partly against a 16% comparison in Q3 2025. Management pointed to benign general surgery, after-hours procedures, growing da Vinci 5 adoption, and new capacity additions as longer-term supports for U.S. growth.

Outside the U.S., benign procedure volume grew 41%. Management sees benign procedures as a major source of international expansion, especially in areas such as hernia repair and cholecystectomy. The company is pairing its tiered system lineup with lower procedure costs to improve the economics for hospitals and outpatient settings.

The most consequential demand and pricing development is the forthcoming reduction in instrument costs. In China, policy-driven changes to charge codes are expected to reduce instruments-and-accessories prices beginning in November. Separately, Intuitive plans to expand the useful life of certain core EndoWrist instruments and introduce volume-based pricing beginning in the first half of 2027.

Management expects the combined actions to reduce da Vinci instruments-and-accessories revenue per procedure by approximately 3% to 5% once fully implemented, holding product, procedure, and geographic mix constant. China will affect results beginning in Q4, while the broader extended-use program will roll out country by country through 2027 and is not expected to reach its full impact until late next year.

Management believes lower costs should increase procedure elasticity over time, particularly in high-volume benign procedures where hospital economics can limit adoption. That thesis is plausible, but the timing and magnitude of the resulting volume response remain central execution variables.

What is Intuitive’s guidance for full-year 2026?

Intuitive narrowed its outlook for worldwide da Vinci procedure growth to approximately 14% to 15% for 2026, compared with its prior 13.5% to 15.5% range. Management expects growth to land closer to the midpoint of the updated range.

The company expects non-GAAP gross margin of 68.7% to 69.3% of revenue for 2026. That range includes an estimated tariff impact of 0.9% of revenue, excluding recognized tariff refunds.

Management maintained its expectation for non-GAAP operating expense growth of 11% to 13% for the year. It also expects non-GAAP other income of $300M to $310M, reduced from prior expectations by lower average cash balances following Q3 share repurchases.

For Q4, Intuitive expects a non-GAAP effective tax rate of approximately 22%, plus or minus 50 basis points.

Balance Sheet, Cash Flow and Capital

Intuitive ended Q3 with $6.80B in cash, cash equivalents, and investments, down from $8.63B at the end of Q2 and $9.03B at year-end 2025.

The quarterly cash decline was driven primarily by $2.94B of share repurchases and $113M of capital expenditures, partly offset by cash generated from operations. The company repurchased 7.8M shares at an average price of $377 per share.

The repurchase reduced diluted weighted-average shares outstanding to 351.6M from 361.8M a year earlier. However, lower cash balances also reduced interest income, with non-GAAP other income declining to $75M from $83M in Q2.

Intuitive also announced plans for a new instruments-and-accessories manufacturing facility in Penang, Malaysia, expected to begin operations in 2028. The project supports anticipated long-term Asian demand but adds to the company’s manufacturing and capital-execution agenda.

What Investors Should Watch

1. U.S. da Vinci Procedure Growth

U.S. da Vinci procedures grew 10% in Q3, while system placements and installed capacity rose more quickly. Investors should watch whether capacity expansion, da Vinci 5 adoption, and penetration of benign general surgery translate into renewed acceleration in U.S. procedures.

2. Pricing Actions and Revenue Per Procedure

China price reductions begin in Q4, while extended-use instruments and volume-based pricing begin rolling out in 2027. The critical issue is whether the expected 3% to 5% mix-constant reduction in da Vinci instruments-and-accessories revenue per procedure is offset by higher procedure volume, stronger system adoption, and mix benefits from da Vinci 5, SP, and Force Feedback instruments.

3. International Adoption and China

International da Vinci procedure growth reached 20%, led by Europe and Asia. China remains more uncertain because of lower recent capital placements, policy-driven price reductions, tender activity, and competitive intensity.

4. Margin Allocation and R&D Investment

Non-GAAP operating margin reached 42% in Q3, but management has indicated it may reinvest part of its margin capacity in new platforms, AI capabilities, clinical evidence, and geographic expansion. Investors should monitor whether investment spending rises faster than revenue as the company pursues new procedure categories and technologies.

5. Litigation Settlement Approval

The proposed $450M antitrust settlement has been recorded but still requires court approval. While the charge is treated as non-recurring in the company’s adjusted results, final approval and the agreed injunctive relief remain relevant to the company’s customer relationships and service model.

AlgovestIQ Takeaway

Intuitive delivered a strong operating quarter. Procedure growth remained in the mid-teens, system placements rose 28%, and revenue grew 22%, showing that customer demand for the da Vinci and Ion platforms remains healthy. The company also expanded gross margin despite tariffs, while its installed base continues to create a larger recurring revenue opportunity.

The reported GAAP earnings decline should be viewed primarily through the proposed litigation settlement. The $450M charge materially reduced GAAP operating income and EPS, but non-GAAP income and margins indicate that the core business remained on a stronger trajectory.

The central investment question is now whether Intuitive can broaden access to robotic surgery without materially weakening its long-term revenue-per-procedure economics. Management is intentionally reducing costs for customers in high-volume benign procedures and China, betting that greater affordability will expand utilization, improve system demand, and increase the addressable market.

Evidence supporting that strategy would include sustained procedure growth in benign surgery, stronger utilization in ambulatory settings, continued international system placements, and increasing adoption of higher-value da Vinci 5, SP, Ion, and Force Feedback offerings. Conversely, weaker revenue per procedure without a corresponding improvement in procedure growth or system demand would challenge the expected return on the pricing actions.

Intuitive retains substantial financial flexibility, a growing installed base, and broad platform momentum. But after a quarter in which revenue growth outpaced procedure growth, investors will need to watch closely whether the company can preserve that relationship as its affordability initiatives begin to affect pricing.